Are you Dr. Yeilding?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
129 Edgewood Rd
Ardmore, PA 19003Phone+1 610-649-6847
Summary
- Dr. Newman Yeilding III, MD is a board certified internist in Ardmore, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1991 - 1995- University of Pennsylvania Health SystemResidency, Internal Medicine, 1985 - 1988
University of Alabama School of MedicineClass of 1985
Certifications & Licensure
PA State Medical License 1987 - 2024- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 183 citationsTumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapyMichael S. Gee, William N. Procopio, Sosina Makonnen, Michael Feldman, Newman M. Yeilding
The American Journal of Pathology. 2003-01-01 - 125 citationsAngiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activityWilliam N. Procopio, Paul I. Pelavin, William M. F. Lee, Newman M. Yeilding
The Journal of Biological Chemistry. 1999-10-15 - 37 citationsPleckstrin 2, a widely expressed paralog of pleckstrin involved in actin rearrangement.Michael H. Hu, Eve Marie Bauman, Richard L. Roll, Newman M. Yeilding, Charles S. Abrams
The Journal of Biological Chemistry. 1999-07-30
Press Mentions
‘Patient-Controlled’ Injector Approved for TremfyaMarch 8th, 2019
Janssen Gets FDA Approval for Tremfya One-Press Patient-Controlled InjectorFebruary 28th, 2019
Janssen Submits Application Seeking FDA Approval of Stelara® (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque PsoriasisDecember 20th, 2018- Join now to see all
